Prognostic markers in localized prostate cancer: From microscopes to molecules

Cancer and Metastasis Reviews

Volumn 17, Issue 4, 1998, Pages 429-437

  Harding, Michael A ^a   Theodorescu, Dan ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Grade; Prognostic markers; Prostate cancer; Stage

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ANGIOGENESIS; APOPTOSIS; ARTIFICIAL NEURAL NETWORK; CANCER GROWTH; CELL CYCLE; HUMAN; HUMAN CELL; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0032780767     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006137721823     Document Type: Review

References (64)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer Statistics, 1998, CA Cancer J Clin 48: 6 ff, 1998
2. Sobin LH, Wittekind C: TNM classification of malignant tumors, 5th edition. John Wiley & Sons, New York, 1997
3. Epstein JI: Incidence and significance of positive margins in radical prostatectomy specimens. Urol Clin North Am 23: 651-63, 1996
4. Gleason DF, Mellinger GT: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111: 58-64, 1974
5. Theodorescu D, Cornil I, Sheehan C, Man S, Kerbel RS: Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spread. Int J Cancer 47: 118-23, 1991
6. Jorgensen T, Yogesan K, Tveter KJ, Skjorten F, Danielsen HE: Nuclear texture analysis: a new prognostic tool in metastatic prostate cancer. Cytometry 24: 277- 83, 1996
7. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr.: Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 80: 2109- 19, 1997
8. Bostwick DG, Wheeler TM, Blute M, Barrett DM, MacLennan GT, Sebo TJ, Scardino PT, Humphrey PA, Hudson MA, Fradet Y, Miller GJ, Crawford ED, Blumenstein BA, Mahran HE, Miles BJ: Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 48: 47-57, 1996
9. Stenman UH: Prostate-specific antigen, clinical use and staging: an overview. Br J Urol 79: 53-60, 1997
10. Vicini FA, Horwitz EM, Gonzalez J, Martinez AA: Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels. J Urol 158: 319-25, 1997
11. Wang MC, Valenzuela LA, Murphy GP, Chu TM: Purification of a human prostate specific antigen. Invest Urol 17: 159-63, 1979
12. Lilja H: Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin. Urol Clin North Am 20: 681-6, 1993
13. Beduschi MC, Oesterling JE: Percent free prostate-specific antigen: the next frontier in prostate-specific antigen testing. Urology 51: 98-109, 1998
14. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. Jama 279: 1542-7, 1998
15. Murphy GP, Barren RJ, Erickson SJ, Bowes VA, Wolfert RL, Bartsch G, Klocker H, Pointner J, Reissigl A, McLeod DG, Douglas T, Morgan T, Kenny GM, Ragde H, Boynton AL, Holmes EH: Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen [published erratum appears in Cancer 1996 Oct 1; 78(7): 1524]. Cancer 78: 809- 18, 1996
16. Arcangeli CG, Humphrey PA, Smith DS, Harmon TJ, Shepherd DL, Keetch DW, Catalona WJ: Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology 51: 558-64; discussion 564-5, 1998
17. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD: Expression of the prostate-specific membrane antigen. Cancer Res 54: 1807-11, 1994
18. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R: Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48: 326-34, 1996
19. Gregorakis AK, Holmes EH, Murphy GP: Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol 16:2-12, 1998
20. Kahn D, Williams RD, Haseman MK, Reed NL, Miller SJ, Gerstbrein J: Radioimmunoscintigraphy with In- 111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol 16: 284-9, 1998
21. Murphy GP, Maguire RT, Rogers B, Partin AW, Nelp WB, Troychak MJ, Ragde H, Kenny GM, Barren RJ 3rd, Bowes VA, Gregorakis AK, Holmes EH, Boynton AL: Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients. Prostate 33: 281-5, 1997
22. Ingenito AC, Ennis RD, Hsu IC, Begg MD, Benson MC, Schiff PB: Re-examining the role of prostate-specific antigen density in predicting outcome for clinically localized prostate cancer. Urology 50: 73-8, 1997
23. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update [see comments] [published erratum appears in JAMA 1997 Jul 9; 278(2): 118]. Jama 277: 1445-51, 1997
24. Epstein JI, Carmichael M, Partin AW, Walsh PC: Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup [see comments]. J Urol 149: 1478-81, 1993
25. Sanchez-Chapado M, Angulo JC, Ibarburen C, Aguado F, Ruiz A, Viano J, Garcia-Segura JM, Gonzalez-Esteban J, Rodriquez-Vallejo JM: Comparison of digital rectal examination, transrectal ultrasonography, and multicoil magnetic resonance imaging for preoperative evaluation of prostate cancer. Eur Urol 32: 140-9, 1997
26. Stapleton AM, Zbell P, Kattan MW, Yang G, Wheeler TM, Scardino PT, Thompson TC: Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 82: 168-75, 1998
27. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 156: 1511-6, 1996
28. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr.: p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 158: 131-7, 1997
29. Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, Epstein JI, Isaacs WB: An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 56: 3814-22, 1996
30. Uzoaru I, Rubenstein M, Mirochnik V, Slobodskoy L, Shaw M, Guinan P: An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer. J Surg Oncol 67: 33-7, 1998
31. Phillips SM, Barton CM, Lee SJ, Morton DG, Wallace DM, Lemoine NR, Neoptolemos JP: Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 70: 1252-7, 1994
32. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL: Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 95: 5246-50, 1998
33. Pesche S, Latil A, Muzeau F, Cussenot O, Fournier G, Longy M, Eng C, Lidereau R: PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 16: 2879-83, 1998
34. Paul R, Ewing CM, Jarrard DF, Isaacs WB: The cadherin cell-cell adhesion pathway in prostate cancer progression. Br J Urol 79: 37-43, 1997
35. Richmond PJ, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M: Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res 57: 3189-93, 1997
36. Noordzij MA, Bogdanowicz JF, van Krimpen C, van der Kwast TH, van Steenbrugge GJ: The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients. J Urol 158: 1880-4; discussion 1884-5, 1997
37. Cussenot O, Villette JM, Cochand-Priollet B, Berthon P: Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors. Prostate Suppl 8: 43- 51, 1998
38. Deftos LJ, Abrahamsson PA: Granins and prostate cancer. Urology 51: 141-5, 1998
39. Abrahamsson PA, Cockett AT, di Sant' Agnese PA: Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma. Prostate Suppl 8: 37-42, 1998
40. Weinstein MH, Partin AW, Veltri RW, Epstein JI: Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 27: 683-7, 1996
41. Kerbel RS: A cancer therapy resistant to resistance [news; comment] [see comments]. Nature 390: 335-6, 1997
42. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA: Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 73: 678- 87, 1994
43. Hawighorst H, Knapstein PG, Knopp MV, Weikel W, Brix G, Zuna I, Schonberg SO, Essig M, Vaupel P, van Kaick G: Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. Cancer Res 58: 3598-602, 1998
44. Ostrowitzki S, Fick J, Roberts TP, Wendland MF, Aldape KD, Mann JS, Israel MA, Brasch RC: Comparison of gadopentetate dimeglumine and albumin-(Gd-DTPA)30 for microvessel characterization in an intracranial glioma model. J Magn Reson Imaging 8: 799-806, 1998
45. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC: Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 4: 623-6, 1998
46. Vogelstein B. Kinzler KW: The multistep nature of cancer. Trends Genet 9: 138-41, 1993
47. Wei JT, Zhang Z, Barnhill SD, Madyastha KR, Zhang H, Oesterling JE: Understanding artificial neural networks and exploring their potential applications for the practicing urologist. Urology 52: 161-72, 1998
48. Douglas TH, Moul JW: Applications of neural networks in urologic oncology. Semin Urol Oncol 16: 35-9, 1998
49. Babaian RJ, Fritsche HA, Zhang Z, Zhang KH, Madyastha KR, Barnhill SD: Evaluation of prostAsure index in the detection of prostate cancer: a preliminary report. Urology 51: 132-6, 1998
50. Tewari A, Narayan P: Novel staging tool for localized prostate cancer: a pilot study using genetic adaptive neural networks [see comments]. J Urol 160: 430-6, 1998
51. Snow PB, Smith DS, Catalona WJ: Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study [see comments]. J Urol 152: 1923-6, 1994
52. Naguib RN, Robinson MC, Neal DE, Hamdy FC: Neural network analysis of combined conventional and experimental prognostic markers in prostate cancer: a pilot study. Br J Cancer 78: 246-50, 1998
53. Ghossein RA, Rosai J, Scher HI, Seiden M, Zhang ZF, Sun M, Chang G, Berlane K, Krithivas K, Kantoff PW: Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology 50: 100-5, 1997
54. Grasso YZ, Gupta MK, Levin HS, Zippe CD, Klein EA: Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. Cancer Res 58: 1456-9, 1998
55. Theodorescu D, Frierson HF, Sikes RA: Molecular determination of surgical margins using fossa biopsies at radical prostatectomy. J Urol 161: 20-24, 1999
56. Ferrari AC, Stone NN, Eyler JN, Gao M, Mandeli J, Unger P, Gallagher RE, Stock R: Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer [see comments]. J Natl Cancer Inst 89: 1498-504, 1997
57. Kamoshida S, Tsutsumi Y:. Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland. Hum Pathol 21: 1108-11, 1990
58. Smith MR, Biggar S, Hussain M: Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases. Cancer Res 55: 2640-4, 1995
59. Troyer JK, Beckett ML, Wright GL Jr.: Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62: 552-8, 1995
60. Fulton RJ, McDade RL, Smith PL, Kienker LJ, Kettman JR Jr.: Advanced multiplexed analysis with the FlowMetrix system. Clin Chem 43: 1749-56, 1997
61. Oliver KG, Kettman JR, Fulton RJ: Multiplexed analysis of human cytokines by use of the FlowMetrix system. Clin Chem 44: 2057-60, 1998
62. Shalon D, Smith SJ, Brown PO: A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Res 6: 639-45, 1996
63. Schena M, Shalon D, Heller R, Chai A, Brown PO, Davis RW: Parallel human genome analysis: microarray- based expression monitoring of 1000 genes. Proc Natl Acad Sci USA 93: 10614-9, 1996
64. Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray [see comments]. Science 270: 467- 70, 1995